|
DEAFNESS, AUTOSOMAL DOMINANT 70
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Whole Exome Sequencing Identified MCM2 as a Novel Causative Gene for Autosomal Dominant Nonsyndromic Deafness in a Chinese Family.
|
26196677 |
2015 |
|
DEAFNESS, AUTOSOMAL DOMINANT 70
|
0.700 |
Biomarker
|
disease |
CLINGEN |
Whole Exome Sequencing Identified MCM2 as a Novel Causative Gene for Autosomal Dominant Nonsyndromic Deafness in a Chinese Family.
|
26196677 |
2015 |
|
DEAFNESS, AUTOSOMAL DOMINANT 70
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
DEAFNESS, AUTOSOMAL DOMINANT 70
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Liver carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Results showed miR-34a-5p expression in HCC tissues was significantly lower than in non HCC liver tissues (P < 0.05), but MCM2 expression in HCC tissues was markedly higher than in non HCC liver tissues (P < 0.05).
|
31034943 |
2019 |
|
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
We also observed that the expression of the MCM2-7 genes was increased in tumor tissue, and diagnostic receiver operating characteristic analysis of MCM2-7 indicated that these genes could serve as sensitive diagnostic markers in HCC.
|
30026832 |
2018 |
|
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Proteomic Analysis and NIR-II Imaging of MCM2 Protein in Hepatocellular Carcinoma.
|
29750532 |
2018 |
|
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
In conclusion, these findings suggest that lnc-FTX may act as a tumor suppressor in HCC through physically binding miR-374a and MCM2.
|
27065331 |
2016 |
|
Liver carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of MCM2 protein related to poor-differentiation in HCC was validated using tissue microarray-based immunohistochemistry containing 96 HCCs.
|
20515756 |
2010 |
|
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
This study also shows that MCM2 and CCNB1 could be promising prognostic and therapeutic targets for HCC.
|
20515845 |
2010 |
|
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
The combination of MCM2, geminin and Ki67 could represent a valuable tool in the understanding of HCC progression in cirrhosis.
|
16629645 |
2006 |
|
Liver carcinoma
|
0.370 |
Biomarker
|
disease |
LHGDN |
The combination of MCM2, geminin and Ki67 could represent a valuable tool in the understanding of HCC progression in cirrhosis.
|
16629645 |
2006 |
|
Malignant tumor of colon
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
RTKN could affect the proliferation and metastasis of colon cancer by reducing expression of MCM2/3/5, CDK1/2 and PCNA, suggesting that RTKN was a potential target for treating colon cancer.
|
26349972 |
2015 |
|
Malignant tumor of colon
|
0.310 |
Therapeutic
|
disease |
CTD_human |
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
|
23770000 |
2013 |
|
Colonic Neoplasms
|
0.310 |
Therapeutic
|
group |
CTD_human |
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells.
|
23770000 |
2013 |
|
Colonic Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity.
|
18465232 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of the present study was to analyze and compare the expression of Mcm-2 in normal oral mucosa (NM) and oral squamous cell carcinomas at tumor margins (TM), the tumor center (TC), and the invasive tumor front (ITF), with correlation of clinicopathologic features.
|
30359334 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry was performed to analyze the expression of MCM2, Ki-67, Cyclin A and PHH3, which were correlated with the following clinicopathological parameters: clinical TNM, tumor grade, biological subtype, the presence of tumor infiltrating lymphocytes (TIL), pathological tumor response rate to the neoadjuvant therapy and patient survival.
|
31446607 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Highly malignant tumors overexpress the minichromosome maintenance 2 (MCM2) protein in the nucleus, which is associated with advanced tumor grade, advanced stage, and poor prognosis.
|
29963273 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Meanwhile, we analyzed the association between MCM2 protein expression and clinicopathological characteristics of LUSC patients, and found high expression of MCM2 protein was obviously associated with malign differentiated degree, advanced clinical stage, large tumor size, more lymph node metastasis and present distant metastasis.
|
30174440 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Particularly, 11 proteins involved in tumor proliferation (MCM2, 4, 6, 7, and MSH2), metastasis (RCC2, CORO1C, CHD4, and IPO9), and cancer metabolism (PHGDH and TYMP) are identified as SCLC-specific proteins.
|
29888431 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, a high-level expression of MCM2 in either primary tumor or metastases of RCC predicted a shorter disease-free survival time, while a high-level expression of MCM4 or MCM6 in primary tumor was also associated with poorer disease-free survival.
|
29180899 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As MCM2 appears to be an attractive alternative to Ki-67, we sought to study the expression of MCM2 and Ki-67 in different histological grades and molecular subtypes of breast cancer focusing primarily on ER-positive tumors.
|
28084344 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Notably, MCM2 and MCM3 expression levels were positively correlated with the DHX9 expression level in tumor samples and were associated with a poor prognosis in patients with osteosarcoma.
|
28460433 |
2017 |